Gene · 64115
Papers2,513
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
241 to 260 of 2,513
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The transcriptomic expression pattern of immune checkpoints shows heterogeneity between and within cancer types. | Am J Cancer Res | 2024 | 38859855 | PubTator, text mining | PubMed |
| TIM-3 transcriptomic landscape with clinical and immunomic correlates in cancer. | Am J Cancer Res | 2024 | 38859842 | PubTator, text mining | PubMed |
| Immunomodulation in Endometriosis: Investigating the interrelationship between VISTA expression and Escherichia.Shigella-Associated metabolites. | Int Immunopharmacol | 2024 | 38852526 | PubTator, text mining | PubMed |
| Expression and Prognostic Significance of LAG-3, TIGIT, VISTA, and IDO1 in Endometrial Serous Carcinoma. | Mod Pathol | 2024 | 38848896 | PubTator, text mining | PubMed |
| Single-cell transcriptomic analysis of the immune microenvironment in pediatric acute leukemia. | Cancer Lett | 2024 | 38844062 | PubTator, text mining | PubMed |
| The VISTA/VSIG3/PSGL-1 axis: crosstalk between immune effector cells and cancer cells in invasive ductal breast carcinoma. | Cancer Immunol Immunother | 2024 | 38833004 | PubTator, text mining | PubMed |
| Immune checkpoint inhibitors: breakthroughs in cancer treatment. | Cancer Biol Med | 2024 | 38801082 | PubTator, text mining | PubMed |
| VISTA: A Novel Checkpoint for Cancer Immunotherapy. | Drug Discov Today | 2024 | 38797321 | PubTator, text mining | PubMed |
| BET inhibition reforms the immune microenvironment and alleviates T cell dysfunction in chronic lymphocytic leukemia. | JCI Insight | 2024 | 38775157 | PubTator, text mining | PubMed |
| LRIG1 engages ligand VISTA and impairs tumor-specific CD8+ T cell responses. | Sci Immunol | 2024 | 38758807 | PubTator, text mining | PubMed |
| Osteomyelitis is associated with increased anti-inflammatory response and immune exhaustion. | Front Immunol | 2024 | 38736874 | PubTator, text mining | PubMed |
| Clinical and Biologic Correlates of ADORA2A Transcriptomic Expression in Cancer. | Int J Mol Sci | 2024 | 38731962 | PubTator, text mining | PubMed |
| Expression patterns of novel immunotherapy targets in intermediate- and high-grade lung neuroendocrine neoplasms. | Cancer Immunol Immunother | 2024 | 38693435 | PubTator, text mining | PubMed |
| H-VISTA Immunohistochemistry Score Is Associated with Advanced Stages in Cutaneous and Ocular Melanoma. | Int J Mol Sci | 2024 | 38673920 | PubTator, text mining | PubMed |
| Targeting Dectin-1 and or VISTA enhances anti-tumor immunity in melanoma but not colorectal cancer model. | Cell Oncol (Dordr) | 2024 | 38668817 | PubTator, text mining | PubMed |
| VISTA/CTLA4/PD1 coexpression on tumor cells confers a favorable immune microenvironment and better prognosis in high-grade serous ovarian carcinoma. | Front Oncol | 2024 | 38634058 | PubTator, text mining | PubMed |
| Co-expression of immune checkpoints in glioblastoma revealed by single-nucleus RNA sequencing and spatial transcriptomics. | Comput Struct Biotechnol J | 2024 | 38633388 | PubTator, text mining | PubMed |
| Do galectins serve as soluble ligands for immune checkpoint receptors? | J Immunother Cancer | 2024 | 38599662 | PubTator, text mining | PubMed |
| VISTA checkpoint inhibition by pH-selective antibody SNS-101 with optimized safety and pharmacokinetic profiles enhances PD-1 response. | Nat Commun | 2024 | 38575562 | PubTator, text mining | PubMed |
| Everolimus treatment enhances inhibitory immune checkpoint molecules' expression in monocyte-derived dendritic cells. | Hum Immunol | 2024 | 38569354 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/64115/papers?page=13